Research groups > TargetsLab Oncology > Breast cancer and lung cancer
Go to content (click on Intro)
UdG Home UdG Home
Close
Menu

New Therapeutic Targets Research Group

Cancer

Breast cancer and lung cancer

According to GLOBOCAN201, lung cancer is the most common in the world, with 2,093,878 cases diagnosed (11.6%) every year, and breast cancer is the second most common, with 2,088,849 (11.6%) cases reported annually.

According to data of the SEOM (Spanish Society of Medical Oncology) based on the Spanish Network of Cancer Registries (REDECAN), lung and breast cancer were the most common types in Spain in 2020, with 29,638 and 32,953 new cases diagnosed respectively.

In Catalonia, the website of the ICO-ICS contains data on patients who have survived a cancer of this type 5 years after the diagnosis. You can view the data of the people treated in the ICO-ICS between 2013 and 2017, sorted into men and women.

Both breast and lung cancer have a rate similar to the population, but lung cancer has a higher mortality rate and therefore a lower prevalence after 5 years than breast cancer.

It is important to highlight that lung cancer went from being the fourth most diagnosed tumour in women in 2015 to the third most diagnosed in 2019. That is, it has been found that there are increasingly more women with lung cancer since 1970, probably related to the increase in smoking in women. There is a latency of approximately 20 years between exposure to the carcinogens of tobacco and the possible development of the illness.

BREAST CANCER

ER/PR+

ER/PR+ breast cancer is characterised by over-expression of the oestrogen and/or progesterone hormone receptors in the cell membrane.

This is the most usual subtype, representing roughly 75% of breast-cancer patients. The current treatments are based on hormonal therapy.

HER2+

HER2+

The breast cancer HER2+ shows an amplification of the gene ERBB2, that an overexpression of the receiver of the factor of epidermic growth means type 2 to the plasma membrane of the cancerous cell..

This subtype corresponds to approximately 20% of patients with breast cancer. Over-expression of HER2 has allowed targeted therapies against this receptor to be developed.

Triple Negative

Triple Negative

Triple negative breast cancer is characterised by not over-expressing oestrogen, progesterone or HER2 receptors. It represent approximately 15% of the patients diagnosed with breast cancer..

There are no therapeutic targets for this type of cancer and it can only be treated with chemotherapy, so the need to find new strategies has intensified.

LUNG CANCER

Lung cancer is classified mainly into two subtypes:

Small cell

Small cell

Small cell lung cancer is also known as microcytic lung cancer. This subtype corresponds to 10-15 % of all lung cancer cases.

Non-small cell

Non-small cell

Non-small cell lung cancer (non-microcytic) is the most common, with 85% of all lung cancer cases being of this type. This type of cancer subdivides into adenocarcinoma (40%), squamous cell carcinoma (30%) and large cell carcinoma (15%).

Choose which types of cookies you accept which the University of Girona can store in your browser.

Those that are essential for enabling your connection. There is no option for disabling them, as they are necessary for the functioning of the website.

These enable your options to be remembered (for example language or region you are accessing from), to provide you with advanced services.

They provide statistical information and enable improved services. We use Google Analytics cookies which you can deactivate by installing this plugin.

To offer advertising contents relating to the interests of users, either directly, or through third parties (“adservers”). These must be activated if you wish to see the YouTube videos uploaded to the University of Girona’s website.